Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31072343 | 1.00 | TLR7 (0.48) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL3274293 | 0.92 | TLR7 (0.42) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL12245181 | 0.91 | TLR7 (0.48) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL31658238 | 0.90 | TLR7 (0.46) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL29551159 | 0.85 | TLR7 (0.54) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL147570 | 0.85 | TLR7 (0.54) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL20836817 | 0.85 | TLR7 (0.50) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL31379717 | 0.84 | TLR7 (0.53) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL144931 | 0.84 | TLR7 (0.53) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL12467809 | 0.83 | TLR7 (0.48) | TLR7TLR8NUDT1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096103-A1 | IMIDAZOQUINOLINE COMPOUNDS | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2013-04-18 | — | — | US | claimed |
| US-20110217323-A1 | IMIDAZOQUINOLINE COMPOUNDS | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2011-09-08 | — | — | US | claimed |
| US-20080213308-A1 | Imidazoquinoline Compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-09-04 | — | — | US | claimed |
| EP-3527224-B1 | RSV IMMUNIZATION REGIMEN | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2025-02-26 | — | — | EP | disclosed |
| US-20250042951-A1 | PRE-FUSION RSV F ANTIGENS | NOVARTIS AG (CH) | 2025-02-06 | — | — | US | disclosed |
| US-12139512-B2 | Pre-fusion RSV F antigens | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-11-12 | — | — | US | disclosed |
| US-20240299527-A1 | RSV IMMUNIZATION REGIMEN | NOVARTIS AG (CH) | 2024-09-12 | — | — | US | disclosed |
| US-20240239845-A1 | PRE-FUSION RSV F ANTIGENS | NOVARTIS AG (CH) | 2024-07-18 | — | — | US | disclosed |
| US-20240050553-A1 | MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS | Seqirus UK Limited (GB) | 2024-02-15 | — | — | US | disclosed |
| US-20240034773-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-02-01 | — | — | US | disclosed |
| US-11827694-B2 | RSV F protein compositions and methods for making same | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-11-28 | — | — | US | disclosed |
| WO-2007052056-A1 | ADJUVANTED INFLUENZA VACCINES INCLUDING CYTOKINE-INDUCING AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007052055-A1 | ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007041432-A2 | CROSS-NEUTRALIZATION OF HCV WITH RECOMBINANT PROTEINS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007011777-A2 | SMALL ANIMAL MODEL FOR HCV REPLICATION | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006091517-A2 | IMMUNOGENS FROM UROPATHOGENIC ESCHERICHIA COLI | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006089264-A2 | PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS/SEPSIS-ASSOCIATED ESCHERICHIA COLI | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006067632-A2 | SACCHARIDE CONJUGATE VACCINES | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006064378-A2 | ADJUVANT ACTIVITY OF GASTROINTESTINAL PEPTIDES | DE MAGISTRIS MARIA TERESA (IT) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006031878-A2 | IMIDAZOQUINOLINE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042951-A1 | PRE-FUSION RSV F ANTIGENS | FURIN, CD69, LY96 | TLR7 485/4885TLR8 1047/4885NUDT1 2589/4885 |
| US-12139512-B2 | Pre-fusion RSV F antigens | FURIN, CD69, LY96 | TLR7 485/4885TLR8 1047/4885NUDT1 2589/4885 |
| US-20130096103-A1 | IMIDAZOQUINOLINE COMPOUNDS | IFNG, IRF3, MYD88 | TLR7 13/4885TLR8 56/4885NUDT1 1316/4885 |
| US-20240299527-A1 | RSV IMMUNIZATION REGIMEN | IL5, IL15, IFNG | TLR7 48/4885TLR8 77/4885NUDT1 3283/4885 |
| US-20110217323-A1 | IMIDAZOQUINOLINE COMPOUNDS | IFNG, IRF3, MYD88 | TLR7 13/4885TLR8 56/4885NUDT1 1316/4885 |
| US-20240239845-A1 | PRE-FUSION RSV F ANTIGENS | FURIN, CD69, LY96 | TLR7 485/4885TLR8 1047/4885NUDT1 2589/4885 |
| US-20240050553-A1 | MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS | CD63, ISG15, ATP6V1B1 | TLR7 515/4885TLR8 279/4885NUDT1 3753/4885 |
| US-11827694-B2 | RSV F protein compositions and methods for making same | RNASEL, TIMCC, RNGTT | TLR7 349/4885TLR8 1489/4885NUDT1 1255/4885 |
| US-20240034773-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | RNASEL, TIMCC, RNGTT | TLR7 349/4885TLR8 1489/4885NUDT1 1255/4885 |
| US-20080213308-A1 | Imidazoquinoline Compounds | IFNG, IRF3, MYD88 | TLR7 13/4885TLR8 56/4885NUDT1 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.